Publications

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

Flaxman A. et al, (2024), PLoS pathogens, 20

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease

Drury RE. et al, (2024), Nature Communications, 15

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T. et al, (2023), iScience, 26

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.

Port JR. et al, (2023), Nature communications, 14

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.

Kaplonek P. et al, (2023), Nature immunology

COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.

Hotez PJ. et al, (2023), BMJ global health, 8

Factors, enablers and challenges for COVID-19 vaccine development.

Excler J-L. et al, (2023), BMJ global health, 8

Vaccine access, equity and justice: COVID-19 vaccines and vaccination.

Privor-Dumm L. et al, (2023), BMJ global health, 8

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface

Zhang P. et al, (2023)

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).

Koen AL. et al, (2023), Vaccine, 41, 3486 - 3492

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Saunders JE. et al, (2023), eBioMedicine, 90, 104523 - 104523

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Madhi SA. et al, (2023), The Lancet. Infectious diseases, 23, 295 - 306

Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.

Vatzia E. et al, (2023), NPJ Vaccines, 8

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209

T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.

McMahon WC. et al, (2023), AIDS (London, England), 37, 105 - 112

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.

van Doremalen N. et al, (2022), NPJ vaccines, 7

Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.

Cable J. et al, (2022), Annals of the New York Academy of Sciences

Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions

Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

van Doremalen N. et al, (2022), Nature Communications, 13

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels

Alharbi NK. et al, (2022), Vaccines, 10

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262

Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters.

Port JR. et al, (2022), bioRxiv

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.

Evans TG. et al, (2022), The Lancet. Infectious diseases, 22, 857 - 866

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

Rosadas C. et al, (2022), Journal of Virological Methods, 302, 114475 - 114475

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination

Sharpe HR. et al, (2022), JCI Insight, 7

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.

van Doremalen N. et al, (2022), Res Sq

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.

Utrilla-Trigo S. et al, (2022), Journal of virology, 96

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

Bosaeed M. et al, (2022), The Lancet Microbe, 3, e11 - e20

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Lambe T. et al, (2021), Communications Biology, 4

Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice

Collins KA. et al, (2021), Scientific Reports, 11

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

Fischer RJ. et al, (2021), Nature communications, 12

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

No one is safe until we are all safe

Gilbert S. and Hatchett R., (2021), Science Translational Medicine, 13

Recombinant protein vaccines against SARS-CoV-2.

Gilbert SC. and Lambe T., (2021), The Lancet. Infectious diseases, 21, 1337 - 1338

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed

Figueroa JP. et al, (2021), PLOS Medicine, 18, e1003772 - e1003772

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Bewley KR. et al, (2021), Science Advances, 7

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.

Hotez PJ. et al, (2021), EClinicalMedicine, 39

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Madhi SA. et al, (2021), The Lancet HIV, 8, e568 - e580

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)

Butler C. et al, (2021), Vaccines, 9, 851 - 851

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.

van Doremalen N. et al, (2021), Science translational medicine, 13

Cookies on this website

Publications